Demitrack, M A, Gold, P W, Dale, J K et al. · Biological psychiatry · 1992 · DOI
This study measured chemical messengers in the blood and spinal fluid of people with ME/CFS and compared them to healthy individuals. Researchers found that people with ME/CFS had lower levels of one chemical (MHPG, related to stress response) and higher levels of another (5-HIAA, related to mood regulation). These differences suggest ME/CFS may have biological markers that distinguish it from purely psychiatric conditions.
This early mechanistic study provided evidence that ME/CFS has measurable biological abnormalities, helping validate it as a distinct medical syndrome rather than a psychiatric disorder. Understanding monoamine metabolism dysfunction may eventually lead to targeted treatments and better diagnostic biomarkers for patients.
This study does not prove that monoamine metabolite abnormalities *cause* ME/CFS symptoms or that restoring normal levels would resolve the illness. The cross-sectional design cannot establish whether these changes precede disease onset or result from it. Correlation between metabolite levels and specific symptoms was not established.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →